로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Protein > NKG2A > NKA-H526c

Human NKG2A / CD159a Protein, Fc Tag

  • 동의어
    NKG2A,CD159a,KLRC1,NK cell receptor A
  • 출처
    Human NKG2A, Fc Tag (NKA-H526c) is expressed from human 293 cells (HEK293). It contains AA Pro 94 - Leu 233 (Accession # P26715-1).
    Predicted N-terminus: Pro
  • 분자 표징
    Online(Pro 94 - Leu 233) P26715-1

    This protein carries a human IgG1 Fc tag at the N-terminus.

    The protein has a calculated MW of 42.5 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 내독소
    Less than 1.0 EU per μg by the LAL method.
  • 순도

    >95% as determined by SDS-PAGE.

  • 레시피

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • 재구성

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 보관

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;

    2. -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE
Human NKG2A, Fc Tag (Cat. No. NKA-H526c) SDS-PAGE gel

Human NKG2A, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • 백그라운드
    NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.
  • Clinical and Translational Updates
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 525,000

가격(KRW) : 3,810,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:5 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop